Junling Liu, Co-founder, Chairman and CEO Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country. Unlike B2C, where businesses...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Canaccord ups TransMedics PT to $46 from $20
Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...
Maxim starts NLS Pharmaceutics at buy; PT $8
Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...
Medtech analyst Raj Denhoy joins Establishment Labs as head of strategy, IR
Establishment Labs Holdings (NASDAQ: ESTA) appointed Raj Denhoy as head of strategy and investor relations to help define and execute the company’s corporate strategy and communicate that vision to investors and other...
Profound Medical appoints healthcare investment professional Cynthia Lavoie to board
Profound Medical (NASDAQ:PROF; TSX:PRN) appointed seasoned healthcare investment professional Cynthia Lavoie, Ph.D., to the board of the commercial-stage medical device company that develops and markets customizable...
Cantor starts Heat Biologics at OW; PT $22
Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...
Analysts start Bolt Biotherapeutics at OP, buy; PTs $36 and $40
Analysts for SVB Leerink and Stifel launched coverage of Bolt Biotherapeutics (NASDAQ:BOLT) with “outperform” and “buy” ratings, respectively, and price targets of $36 and $40, respectively. The stock closed at $30 on...
Stifel starts Angion Biomedica at buy; PT $40
Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)...
SVB Leerink starts Pharvaris at OP; PT $50
SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...
Piper starts Avita Medical at OW; PT $27
Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...
WB starts Lucira Health at OP
William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...
Ladenburg starts Evaxion Biotech at buy; PT $23
Ladenburg Thalmann initiated coverage of Evaxion Biotech A/S (NASDAQ:EVAX) with a “buy” rating and $23 price target. The stock closed at $7.08 on March 1. Evaxion is a clinical-stage artificial intelligence (AI)...
AGP ups Sensus Healthcare PT to $7.50 from $2.95
Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...
Just a few of the companies we’ve highlighted along the way
